Background Sublingual formulations of buprenorphine (BUP) and BUP/naloxone have well-established pharmacokinetic and pharmacodynamic profiles, and so are effective and safe for treating opioid use disorder. in a little mass ( 0.03 g/kg per scan) to make sure only sub-pharmacological amounts that occupy 0.3C0.6% of ORs. Fifty percent the total dosage was administered like a bolus… Continue reading Background Sublingual formulations of buprenorphine (BUP) and BUP/naloxone have well-established pharmacokinetic